Molecular Partners Ag (MOLN) Change in Accured Expenses (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Change in Accured Expenses of -$3050.8 for Q1 2026, down 16.27% year-over-year from -$3643.7 in Q1 2025, and up 99.88% quarter-over-quarter from -$2.5 million in Q3 2025.
Molecular Partners Ag (MOLN) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Change in Accured Expenses for 6 consecutive years, with -$3050.8 the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -3,050.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,050.76 |
| Mar 31, 2026 | -3,050.76 |
| Sep 30, 2025 | -2.49 Mn |
| Sep 30, 2025 | -2.49 Mn |
| Jun 30, 2025 | 2.41 Mn |
| Jun 30, 2025 | 2.41 Mn |
| Mar 31, 2025 | -2,623.80 |
| Mar 31, 2025 | -2,623.80 |
| Sep 30, 2024 | 971,024.17 |
| Sep 30, 2024 | 971,024.17 |
| Jun 30, 2024 | -929,315.48 |
| Jun 30, 2024 | -929,315.48 |
| Mar 31, 2024 | -1,826.22 |
| Mar 31, 2024 | -1,826.22 |
| Sep 30, 2023 | 1.82 Mn |
| Sep 30, 2023 | 1.82 Mn |
| Jun 30, 2023 | -1.79 Mn |
| Jun 30, 2023 | -1.79 Mn |
| Mar 31, 2023 | -2,852.11 |
| Mar 31, 2023 | -2,852.11 |